PRESS RELEASE published on 05/17/2023 at 12:30, 2 years 10 months ago Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis
PRESS RELEASE published on 05/06/2023 at 12:30, 2 years 11 months ago Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action
PRESS RELEASE published on 05/04/2023 at 12:30, 2 years 11 months ago Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders
PRESS RELEASE published on 04/27/2023 at 12:30, 2 years 11 months ago Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.
PRESS RELEASE published on 04/26/2023 at 12:30, 2 years 11 months ago Immunic to Participate in Investor and Scientific Conferences in May
PRESS RELEASE published on 04/05/2023 at 12:30, 3 years ago Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis
PRESS RELEASE published on 03/02/2023 at 12:30, 3 years 1 month ago Immunic to Participate in Investor and Scientific Conferences in March
PRESS RELEASE published on 02/22/2023 at 12:30, 3 years 1 month ago Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023
PRESS RELEASE published on 02/09/2023 at 12:30, 3 years 2 months ago Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need
PRESS RELEASE published on 01/25/2023 at 12:30, 3 years 2 months ago Immunic to Participate in Scientific and Investor Conferences in February
Published on 04/09/2026 at 19:15, 53 minutes ago Murchison Minerals Announces Adoption of Quarterly Reporting Exemption Under Coordinated Blanket Order 51-933
Published on 04/09/2026 at 16:00, 4 hours 8 minutes ago Banff Half Marathon Completes 2025 Emissions Assessment, Supporting Climate Action with Karbon-X
Published on 04/09/2026 at 14:40, 5 hours 28 minutes ago Silver X Delivers Production Growth During the First Quarter of 2026
Published on 04/09/2026 at 14:00, 6 hours 8 minutes ago Orogen Royalties Announces Mineral Reserve and Resource Update on Producing Ermitaño Royalty
Published on 04/09/2026 at 13:30, 6 hours 38 minutes ago Datametrex Receives $6M Purchase Order for Data Centre from Fortune 500 Conglomerate
Published on 04/09/2026 at 18:15, 1 hour 53 minutes ago REPLY: Launch of a share buyback program for a maximum number of 3,607,950 shares
Published on 04/09/2026 at 15:40, 4 hours 28 minutes ago Form 8.3 - The Vanguard Group, Inc.: LondonMetric Property plc
Published on 04/09/2026 at 15:39, 4 hours 28 minutes ago Form 8.3 - The Vanguard Group, Inc.: Schroders plc
Published on 04/09/2026 at 18:35, 1 hour 33 minutes ago Availability of proxy documents for the Combined General Meeting of April 30, 2026
Published on 04/09/2026 at 15:57, 4 hours 10 minutes ago Filing of CNP Assurances SA 2025 universal registration document and 2025 Solvency and Financial Condition Reports
Published on 04/09/2026 at 07:00, 13 hours 8 minutes ago bioMérieux Unveils its BIOFIRE® SPOTFIRE® Molecular Testing Solution for the Pharmaceutical Industry, Redefining Rapid Mycoplasma Testing
Published on 04/08/2026 at 18:02, 1 day 2 hours ago Publication of the 2025 Universal Registration Document
